Viatris Inc
VTRS evidence brief
What we can confirm
- BioSniper Score:
- 8.9 / 10
- Market Cap:
- $19.08B
- Lead Asset:
- astepro (Approved)
What it means
What to watch
Prepared research question
What matters most for VTRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VTRS
Viatris Inc (VTRS) is a global healthcare company with a diversified portfolio of generics and specialty pharmaceuticals, advancing a pipeline of novel therapies including selatogrel, cenerimod, and VR-205.
Key risk: Patent expirations on key products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 9 pipeline candidates · 44 clinical trials · 5 catalysts · 9 FDA decisions for Viatris Inc.
Viatris Inc (VTRS) is a global healthcare company with a diversified portfolio of generics and specialty pharmaceuticals, advancing a pipeline of novel therapies including selatogrel, cenerimod, and VR-205.
- Total Revenues of $14.3 billion [sec · filed 2026-04-02]
- Cash & equivalents of $886.5M as of 2026-06-30 [sec]
- Positive Phase 3 results for VR-205 (Nefecon) in Japanese IgAN patients; NDA filing planned by end-2026 [news · published 2026-06-29]
- FDA accepted NDA for MR-107A-02, a fast-acting non-opioid meloxicam formulation [news · published 2026-05-24]
- Completed 60 regional transactions including acquisition of Aculys Pharma in Japan [sec · filed 2026-04-02]
What works
- Strong cash generation: free cash flow doubled year-over-year in Q2 2026 [news · published 2026-09-09]
- Pipeline progress with five positive Phase 3 readouts and continued advancement of selatogrel and cenerimod [sec · filed 2026-04-02]
- Returned more than $1 billion to shareholders through dividends and share repurchases [sec · filed 2026-04-02]
What to weigh
- Patent expirations on key products (e.g., AZELASTINE HYDROCHLORIDE in 2028, SILDENAFIL CITRATE in 2030) could pressure base business [catalyst]
- Reliance on pipeline catalysts (selatogrel, cenerimod) for future growth; these are still in clinical development [sec · filed 2026-04-02]
- Past earnings pressure noted, though momentum is building [news · published 2026-05-24]
From the filings
Quoted directly from source documents.
Total Revenues of $14.3 billion
“$14.3 billion in Total Revenues”
SEC filings · April 2, 2026
Positive Phase 3 results for VR-205 in Japanese IgAN patients
“positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN)”
News · June 29, 2026
FDA accepted NDA for MR-107A-02
“FDA accepted its New Drug Application for MR-107A-02, a fast acting, non opioid meloxicam formulation for moderate to severe acute pain”
News · May 24, 2026
Free cash flow doubled year-over-year
“free cash flow doubled year-over-year”
News · September 9, 2026
Catalyst timeline
- 2028-06-04 · Patent_Expiry · AZELASTINE HYDROCHLORIDE — Patent expiry for NDA022203; may open market to generic competition.
- 2030-01-31 · Patent_Expiry · SILDENAFIL CITRATE — Patent expiry for NDA021845; could affect revenue from this product.
- 2030-11-04 · Patent_Expiry · TOBRAMYCIN — Patent expiry for NDA201688; potential generic entry.
- 2031-02-25 · Patent_Expiry · ZOLPIDEM TARTRATE — Patent expiry for NDA021997; may impact sales.
- 2035-10-19 · Patent_Expiry · VARENICLINE TARTRATE — Patent expiry for NDA213978; long-term risk to revenue.
Risks & what to watch (3)›
Key risks
- Patent expirations on key products — Patent expirations for AZELASTINE HYDROCHLORIDE (2028), SILDENAFIL CITRATE (2030), and others may erode base business revenue [catalyst]
- Pipeline dependency for growth — Future growth relies on pipeline assets (selatogrel, cenerimod) still in clinical development; no guarantee of approval [sec · filed 2026-04-02]
- Past earnings pressure — Momentum is building but past earnings pressure noted; share price recovery may be fragile [news · published 2026-05-24]
What to watch
- NDA filing for VR-205 (Nefecon) in Japan by end-2026 [news · published 2026-06-29]
- FDA review of MR-107A-02 NDA for acute pain [news · published 2026-05-24]
- Phase 3 data readouts for selatogrel and cenerimod [sec · filed 2026-04-02]
- Patent expirations starting 2028 and their impact on generics revenue [catalyst]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Viatris Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Viatris Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
0% dilution
Lead: Approved
9 candidates
5 upcoming, next in ~599d
0 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 3.3%
- Days to cover
- 4.0
- Shares short
- 37,783,688
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VTRS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Viatris Inc?
Viatris Inc (VTRS) is a global healthcare company with a diversified portfolio of generics and specialty pharmaceuticals, advancing a pipeline of novel therapies including selatogrel, cenerimod, and VR-205.
What is Viatris Inc's lead drug candidate?
Viatris Inc's most advanced tracked candidate is astepro (Approved) for Uses Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: nasal congestion runny nose sneezing itchy nose.
What is Viatris Inc's next catalyst?
Viatris Inc's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022203" — expected June 4, 2028.
Who is the CEO of Viatris Inc?
Mr. Scott Andrew Smith Ph.D. is the chief executive officer of Viatris Inc (VTRS).
Where is Viatris Inc headquartered?
Viatris Inc (VTRS) is headquartered in Canonsburg, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.